Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis
Diabetes Obes Metab 2024 Dec 06;[EPub Ahead of Print], Y Bao, Y Hu, M Shi, Z ZhaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.